Last reviewed 2026-04-19 · How we verify

NA-931 dose 3, daily and orally

Biomed Industries, Inc. · Phase 2 active Small molecule

NA-931 dose 3, daily and orally is a Small molecule drug developed by Biomed Industries, Inc.. It is currently in Phase 2 development. Also known as: NA=931, NA-931.

At a glance

Generic name	NA-931 dose 3, daily and orally
Also known as	NA=931, NA-931
Sponsor	Biomed Industries, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NA-931 dose 3, daily and orally CI brief — competitive landscape report
NA-931 dose 3, daily and orally updates RSS · CI watch RSS
Biomed Industries, Inc. portfolio CI

Frequently asked questions about NA-931 dose 3, daily and orally

What is NA-931 dose 3, daily and orally?

NA-931 dose 3, daily and orally is a Small molecule drug developed by Biomed Industries, Inc..

Who makes NA-931 dose 3, daily and orally?

NA-931 dose 3, daily and orally is developed by Biomed Industries, Inc. (see full Biomed Industries, Inc. pipeline at /company/biomed-industries-inc).

Is NA-931 dose 3, daily and orally also known as anything else?

NA-931 dose 3, daily and orally is also known as NA=931, NA-931.

What development phase is NA-931 dose 3, daily and orally in?

NA-931 dose 3, daily and orally is in Phase 2.

Manufacturer: Biomed Industries, Inc. — full pipeline
Also known as: NA=931, NA-931